Participated · Series A · Jun 2026

Led by founder and CEO Chamath Palihapitiya, 8090 Labs develops an "AI-enabled Software Factory" engineered to design new systems, refactor legacy code bases, and automate software delivery pipelines. The company targets enterprise customers in highly regulated sectors including healthcare, aerospace, financial services, energy, and the U.S. government. Following its $135M Series A, 8090 intends to scale by accelerating corporate hiring, expanding its technical team, and investing in high-performance compute and infrastructure. The business is backed by institutional investors and prominent angels, positioning it to expand operations and customer deployments. No prior funding rounds or specific revenue or user metrics were disclosed in the article.

Led · Series A · Jan 2025

PinkDx is an early-stage company based in Daly City, California that applies advanced science and technology to address medical problems unique to women. Its lead program is a diagnostic test intended to clarify diagnoses for women who present with general symptoms that may signal a gynecologic cancer. The company aims to replace invasive diagnostic procedures, reduce delays in obtaining answers, and enable faster, more appropriate care for patients and physicians. PinkDx reports progress in discovery and development and is advancing the test toward clinical validation. The company completed an upsized Series A round totaling $45 million to support development and clinical validation toward commercialization. As part of BEVC's investment, PinkDx joined Bakar Labs, linking the company to UC Berkeley's life-science incubator and strategic resources. PinkDx is an early-stage, Daly City, CA–based company focused on positively impacting the health of women across their life journey. Led by cofounder, chairwoman and CEO Bonnie Anderson, with CSO Giulia C. Kennedy, Ph.D., and CFO/Chief Business Officer Tim McMeekan, the company applies scientific approaches to address medical problems affecting women. Its first indication targets overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. PinkDx will use the Series A proceeds to advance test development, initially focusing on gynecological cancers. The company also appointed Alison Cowan, M.D., M.S.C.R., as chief medical officer to guide clinical development; she previously led Medical Affairs at Mirvie and served as medical director for Hologic’s Diagnostics division.

Led · Equity · Nov 2024

EarthOptics leverages advances in soil-sensing technologies, genomics, and data science to deliver predictive insights into chemical, physical, and biological soil properties. It combines lab-based analysis with field-based sensors to give farmers and ranchers actionable recommendations to optimize spending and unlock sustainable farming opportunities. The company completed a strategic merger with Pattern Ag, combining EarthOptics’ proprietary field-based sensing technologies with Pattern Ag’s lab-based analysis to offer comprehensive soil data. Led by CEO Lars Dyrud, EarthOptics operates offices in Raleigh, North Carolina; Emeryville, California; Arlington and Blacksburg, Virginia; Minneapolis, Minnesota; and Fayetteville, Arkansas, and maintains two laboratories in Emeryville and Memphis, Tennessee. The company intends to use new funding to accelerate technological innovation, broaden its geographic reach, and consolidate its position as an authoritative source for soil insights. EarthOptics develops next-generation soil-sensing technologies that combine ground-based sensors, satellites, physical soil samples, machine learning models, and agronomic expertise to deliver detailed soil measurements. The company's platform provides insights to help farmers optimize fertilizer applications, inform tillage decisions, and quantify carbon sequestration. EarthOptics plans to use its latest funding to expand access to its tools and deliver hyper-accurate soil insights. Founded in 2018 and based in Arlington, VA, the company serves growers and ranchers seeking data-driven land-management decisions. The company is led by CEO Lars Dyrud. The article reports a recent financing that will support its growth and product expansion efforts. EarthOptics has developed an imaging suite that uses ground-penetrating radar and electromagnetic induction to produce deep maps of soil physical and chemical composition. Its commercial products, GroundOwl and C-Mapper (C for carbon), reconcile no-contact sensor data with traditional lab samples via machine learning trained on tens of thousands of ground-truth measurements. The hardware can be mounted on ordinary tractors or trucks and pulls readings every few feet, reducing physical sampling from hundreds of samples to dozens. The company’s outputs can be used to create meter-scale treatment maps or to feed variable-depth robotic field machinery such as smart tillers. Management positions the product as a cheaper, faster, and more precise alternative to traditional soil sampling and as foundational data for automated and robotic farming. Financially, EarthOptics raised a $10.3M A round to scale its two existing products and to develop a moisture-mapping product.

Participated · Equity · Oct 2023

Triplebar’s core product is its Hyper‑Throughput™ screening platform, described as a “microprocessor for biology” that integrates hardware, software, biology and biochemistry to miniaturize and accelerate evolution. The platform is used to develop biological systems for low-cost, low-footprint animal proteins, improve performance of animal cell lines for cellular meat, and discover novel therapeutic biologic candidates. Triplebar positions itself as a multi-product, multi-vertical product design engine serving food, nutrition and healthcare verticals, including bioactives, functional food proteins, cultured meat, and novel biologics. The company works with commercial partners and corporate collaborators to scale manufacturing via fermentation and cell-line optimization without genetic modification. Recent partnerships include collaboration with Umami Bioworks on cultivated seafood cell lines and with FrieslandCampina to co-develop scalable nutritional ingredients. Triplebar announced $20M in new funding to expand its product portfolio across food and biopharmaceuticals.

Participated · Equity · Aug 2022

PatternAg offers a metagenomics platform that uses genomic sequencing to generate data-driven, evidence-based, long-term predictions about pest, disease, and fertility risks for next season’s row crops. The system produces actionable predictions that help farmers leverage soil biology, increase profitability, and reduce reliance on traditional industrial crop chemistry inputs. Founded in 2018 and led by CEO Rob Hranac, the company operates a corporate office in Emeryville, CA, with field teams located throughout the Midwest. PatternAg intends to use the new funding to accelerate growth and expand operations. The article does not disclose revenue or user metrics. PatternAg develops metagenomic soil‑health analytics that let growers see what’s living in their soil and tailor fertility and crop‑protection inputs to the field’s microbiome. The company aims to enable precision microbiome engineering to improve farm productivity and sustainability over time. It is headquartered in Emeryville, California, was founded in 2018, and operates field teams in six Midwestern states. PatternAg recently closed an additional funding round that brought on investors including The Nature Conservancy, iSelect Fund, and LAUNCH alongside existing backers such as Valor Capital Group and Founders Fund. The firm said it will use the new funds to strengthen ties with existing soil‑health initiatives and to enhance its analytics to make recommendations more relevant and actionable for growers. Leadership frames the work as both environmentally beneficial and economically practical for farmers. PatternAg uses metagenomic DNA sequencing to map the microbial community in soil and deliver actionable intelligence for crop protection and input optimization. Its crop protection product identifies key risks such as Corn Rootworm and Soybean Cyst Nematode, enabling growers to adjust inputs to maximize yield or save money. In its first season in market the company signed farmers across seven Midwestern states covering roughly half a million corn and soybean acres and reports helping customers increase profits up to $50 per acre. PatternAg was incubated at The Production Board, was founded in 2018, and is headquartered in Emeryville, California, with field teams in six Midwestern states. The company plans to use recent funding to scale its biological analytics offering across the US and into international markets such as Brazil, and to expand its product set to better manage soil health and nutrients. PatternAg says it currently uses about 1% of the genetic data from each soil core for its core product and intends to unlock the remaining data for growers.